Where Are Nucleic Acid Therapeutics Heading? — Trends in Next-Generation Drug Discovery and Luxna Biotech’s Perspective (Featuring a Contribution by our President & CEO, Hideaki Sato) 2026/06/12 Notice > Interview Read
Luxna Biotech and KH Neochem Launch Joint Research to Advance Next-Generation Deliverable Nucleic Acid Therapeutics 2026/03/30 Notice Read
Announcement of License Agreement with Inabata & Co., Ltd. regarding the Manufacture and Sales of the Xeno-Modified Nucleic Acid Amidite “GuNA™” 2026/03/13 Notice Read
Announcement of License Agreement with BioSpring GmbH for the Manufacture of Oligonucleotides Using XNA Technology 2025/10/09 Notice Read
Our Senior Scientist, Kawanobe Ph.D., the first author, published in Nucleic Acid Therapeutics collaborative research with Axcelead Drug Discovery Partners, Inc. using XNAs technology. 2025/03/27 Notice Read
